

P.O. Box 806  
Pelham, N.Y. 10803  
Telephone: (914) 712-0093  
Fax: (914) 712-0094/5

Cheryl H. Agris, Ph.D.  
Attorney at Law

OFFICIAL

RECEIVED  
CENTRAL FAX CENTER

SEP 26 2003

Fax

To: Jennifer Kim From: Cheryl Agris  
Fax: 1-703-308-4556 Pages: 5  
Phone: Date: 9/25/03  
Re: 5739.200(09/450,609) CC:  
☐ Urgent ☒ For Review ☐ Please Comment ☐ Please Reply

• Comments:

See attached

NOTICE OF CONFIDENTIALITY

The information contained in and transmitted with this facsimile is subject to the attorney-client privilege, attorney work product, or is confidential and is intended only for the individual or entity designated above. You are hereby notified that any dissemination, distribution, copying, or use of or reliance upon the information contained in and transmitted with this facsimile by or to anyone other than the recipient designated above by the sender is unauthorized and strictly prohibited. If you have received this facsimile in error or did not receive all pages, please notify Cheryl H. Agris, Ph.D. Attorney at Law at (914) 712-0093 immediately.

Attorney Docket No.: 5739.200-US

PATENT

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Weibel et al.

Application No.: 09/450,609

Group Art Unit: 1617

Filed: November 30, 1999

Examiner: Kim, J.

For: New Pharmaceutical Composition And The Process For Its Preparation

Confirmation No.: 7926

OFFICIAL

RECEIVED  
CENTRAL FAX CENTER

SEP 26 2003

CERTIFICATE OF FACSIMILE TRANSMISSIONCommissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

I hereby certify that the attached correspondence comprising:


1. RCE Transmittal (in duplicate)

is being transmitted via telefax to Examiner J. Kim at (703) 308-4556.

Respectfully submitted,

Date:

9/25/03



Cheryl H. Agnis, Reg. No. 34,086

Outside Counsel for

Novo Nordisk Pharmaceuticals, Inc.

100 College Road West

Princeton, N.J. 08540

Attorney Docket No.: 5739.200-US

PATENT

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Weibel et al.

Application No.: 09/450,609

Group Art Unit: 1617

Filed: November 30, 1999

Examiner: Kim, J.

For: New Pharmaceutical Composition And The Process For Its Preparation

Confirmation No.: 7926

## REQUEST FOR CONTINUED EXAMINATION (RCE) TRANSMITTAL

Mail Stop RCE  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

This is a request for Continued Examination (RCE) under 37 C.F.R. §1.114 of the above identified application.

## 1. Submission required under 37 C.F. R. § 1.114

a. ☒ Previously submitted

- i. ☒ Consider the amendment(s)/reply under 37 C.F.R. § 1.116 previously filed on July 24, 2003
- ii. ☐ Consider the arguments in the Appeal Brief of Reply Brief previously filed on
- iii. ☐ Other

b. ☐ Enclosed

- i. ☐ Amendment / Reply
- ii. ☐ Affidavit(s)/Declaration(s)
- iii. ☐ Information Disclosure Statement (IDS)
- iv. ☐ Other-Substitute Specification

**2. Miscellaneous**

a. ☐ Suspension of action on the above-identified application is requested under 37 C.F.R. § 1.103 (c) for a period of \_\_\_\_\_ months. (period of suspension shall not exceed 3 months, Fee under 37 C.F.R. § 1.17 (i) required)

b. ☐ Other

3. In the event that an extension of time is required, Applicant hereby petitions for such extension of time. The Commissioner of Patents is authorized to charge the required fee, if applicable, to Deposit Account 14-1447.

**4. Fees**

☒ The Director is hereby authorized to charge the following fees, any extra fees, or credit any overpayments, to Deposit Account No. 14-1447.

- i. ☒ RCE fee required under 37 C.F.R. § 1.17 (e) of \$740.00
- ii. ☒ Extension of time fee (37 C.F.R. §§ 1.136 and 1.17) of 3 months (difference between three months and one month: \$930-\$110=\$820)

A duplicate of this sheet is enclosed.

Respectfully submitted,

Date:

9/25/03

*Cheryl H. Agris*

Cheryl H. Agris, Reg. No. 34,086  
Novo Nordisk Pharmaceuticals, Inc.  
100 College Road West  
Princeton, NJ 08540

RECEIVED  
CENTRAL FAX CENTER

SEP 26 2003

OFFICIAL